Allosteric and orthosteric binding modes of two nonpeptide human gonadotropin-releasing hormone receptor antagonists

Biochemistry

Volumn 45, Issue 51, 2006, Pages 15327-15337

  Sullivan, Susan K ^a,b   Brown, Michael S ^a   Gao, Yinghong ^a   Loweth, Colin J ^a   Lio, Francisco M ^a   Crowe, Paul D ^a   Struthers, R Scott ^a   Betz, Stephen F ^a  

^a Neurocrine Biosciences ^*  (United States)

^b Synteract Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOSTERIC TERNARY COMPLEX MODEL; ORTHOSTERIC BINDING; RADIOLABELED PEPTIDE AGONISTS; THERAPEUTICS;

AMINO ACIDS; CHEMICAL BONDS; COMPLEXATION; DISEASES; NITROGEN COMPOUNDS;

HORMONES;

1 (2,6 DIFLUOROBENZYL) 3 (AMINO 2 PHENETHYL) 5 (2 FLUORO 3 METHOXYPHENYL) 6 METHYLURACIL; FURAN 1; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; GONADOTROPIN RELEASING HORMONE[5 HISTIDINE 6 DEXTRO TYROSINE I 125]; HORMONE ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; NBI 42902; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; COMPLEX FORMATION; DRUG BINDING SITE; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; INFERTILITY; ISOTOPE LABELING; KINETICS; MODEL; NONHUMAN; PRIORITY JOURNAL;

ALLOSTERIC REGULATION; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; FURANS; HORMONE ANTAGONISTS; HUMANS; INHIBITORY CONCENTRATION 50; MUTAGENESIS, SITE-DIRECTED; RADIOLIGAND ASSAY; RATS; RECEPTORS, LHRH; STEREOISOMERISM; THYMINE;

EID: 33845958682     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi0617097     Document Type: Article

References (72)

1. Cheng, K. W., and Leung, P. C. (2000) The expression, regulation and signal transduction pathways of the mammalian gonadotropin-releasing hormone receptor, Can. J. Physiol. Pharmacol. 78, 1029-52.
2. Fink, G. (1988) in The Physiology of Reproduction (Knobil, E. N., Jr., Ed.) pp 1349-77, Raven Press, New York.
3. Millar, R. P., Lu, Z. L., Pawson, A. J., Flanagan, C. A., Morgan, K., and Maudsley, S. R. (2004) Gonadotropin-releasing hormone receptors, Endocr. Rev. 25, 235-75.
4. 2+ mobilizing hormones: The case of gonadotropin-releasing hormone, Endocr. Rev. 11, 326-53.
5. Conn, P. M., and Crowley, W. F., Jr. (1994) Gonadotropin-releasing hormone and its analogs, Annu. Rev. Med. 45, 391-405.
6. Kiesel, L. A., Rody, A., Greb, R. R., and Szilagi, A. (2002) Clinical use of GnRH analogs, Clin. Endocrinol. 56, 677-87.
7. Lunenfeld, B. (1999) GnRH Analogues: The state of the art at the millennium, The Parthenon Publishing Group, New York.
8. Barbieri, R. L. (1992) Hormone treatment of endometriosis: The estrogen threshold hypothesis, Am. J. Obstet. Gynecol. 166, 740-5.
9. Emons, G., and Schally, A. V. (1994) The use of leutenizing releasing hormone agonists and antagonists in gynaecological cancers, Hum. Reprod. 9, 1364-79.
10. Millar, R. P., Zhu, Y. F., Chen, C., and Struthers, R. S. (2000) Progress towards the development of non-peptide orally-active gonadotropin-releasing hormone (GnRH) antagonists: Therapeutic implications, Br. Med. Bull. 56, 761-72.
11. Grundker, C., and Emons, G. (2003) Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer, Reprod. Biol. Endocrinol. 1, 65.
12. Herbst, K. L. (2003) Gonadotropin-releasing hormone antagonists, Curr. Opin. Pharmacol. 3, 660-6.
13. Huirne, J. A., and Lambalk, C. B. (2001) Gonadotropin-releasing-hormone- receptor antagonists, Lancet 358, 1793-803.
14. Goulet, M. T. (1995) Gonadotropin releasing hormone antagonists, in Annual Reports in Medicinal Chemistry, pp 169-78, Academic Press Inc., New York.
15. Tomera, K., Gleason, D., Gittelman, M., Moseley, W., Zinner, N., Murdoch, M., Menon, M., Campion, M., and Garnick, M. B. (2001) The gonadotropin- releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer, J. Urol. 165, 1585-9.
16. Garnick, M. B., and Campion, M. (2000) Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: Differential effects on follicle-stimulating hormone. Abarelix Depot study group, Mol. Urol. 4, 275-7.
17. Halmos, G., Schally, A. V., Pinski, J., Vadillo-Buenfil, M., and Groot, K. (1996) Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix, Proc. Natl. Acad. Sci. U.S.A. 93, 2398-402.
18. Coccia, M. E., Comparetto, C., Bracco, G. L., and Scarselli, G. (2004) GnRH antagonists, Eur. J. Obstet. Gynecol. Reprod. Biol. 1158, S44-56.
19. Armer, R. E., and Smelt, K. H. (2004) Non-Peptidic GnRH Receptor Antagonists, Curr. Med. Chem. 11, 3017-28.
20. Zhu, Y. F., Chen, C., and Struthers, R. S. (2004) Nonpeptide Gonadotropin Releasing Hormone Antagonists, Annu. Rep. Med. Chem. 39, 99-110.
21. Betz, S. F., Reinhart, G. J., Lio, F. M., Chen, C., and Struthers, R. S. (2006) Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor, J. Med. Chem. 49, 637-47.
22. Betz, S. F., Lio, F. M., Gao, Y., Reinhart, G. J., Guo, Z., Mesleh, M. F., Zhu, Y. F., and Struthers, R. S. (2006) Determination of the Binding Mode of Thienopyrimidinedione Antagonists to the Human Gonadotropin Releasing Hormone Receptor Using SAR, Site-Directed Mutagenesis, and Homology Modeling, J. Med. Chem. (in press).
23. Christopoulos, A., and Kenakin, T. (2002) G protein-coupled receptor allosterism and complexing, Pharmacol. Rev. 54, 323-74.
24. May, L. T., Avlani, V. A., Sexton, P. M., and Christopoulos, A. (2004) Allosteric Modulation of G protein-coupled receptors, Curr. Pharm. Des. 10, 2003-13.
25. Lazareno, S., and Birdsall, N. J. (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: Interactions of strychnine and acetylcholine at muscarinic receptors, Mol. Pharmacol. 48, 362-78.
26. Christopoulos, A., May, L. T., Avlani, V. A., and Sexton, P. M. (2004) G protein-coupled receptor allosterism: The promise and the problem(s), Biochem. Soc. Trans. 32, 873-7.
27. Bruns, R. F., and Fergus, J. H. (1990) Allosteric enhancement of adenosine Al receptor binding and function by 2-amino-3-benzoylthiophenes, Mol. Pharmacol. 38, 939-49.
28. 1 receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding, J. Med. Chem. 42, 3629-35.
29. 1 adenosine receptors, J. Med. Chem. 45, 382-9.
30. Lutjens, H., Zickgraf, A., Figler, H., Linden, J., Olsson, R. A., and Scammells, P. J. (2003) 2-Amino-3-benzoylthiophene allosteric enhancers of Al adenosine agonist binding: New 3, 4-, and 5-modifications, J. Med. Chem. 46, 1870-7.
31. Jakubik, J., Bacakova, L., Lisa, V., el-Fakahany, F. F., and Tucek, S. (1996) Activation of muscarinic acetylcholine receptors via their allosteric binding sites, Proc. Natl. Acad. Sci. U.S.A. 93, 8705-9.
32. 2 receptors, Mol. Pharmacol. 56, 962-5.
33. Zahn, K., Eckstein, N., Trankle, C., Sadee, W., and Mohr, K. (2002) Allosteric modulation of muscarinic receptor signaling: Alcuronium-induced conversion of pilocarpine from an agonist into an antagonist, J. Pharmacol. Exp. Ther. 301, 720-8.
34. Avlani, V., May, L. T., Sexton, P. M., and Christopoulos, A. (2004) Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors, J. Pharmacol. Exp. Ther. 308, 1062-72.
35. May, L. T., Lin, Y., Sexton, P. M., and Christopoulos, A. (2005) Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators, J. Pharmacol. Exp. Ther. 312, 382-90.
36. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568, Mol. Pharmacol. 53, 1083-8.
37. Nemeth, E. F., Heaton, W. H., Miller, M., Fox, J., Balandrin, M. F., Van Wagenen, B. C., Colloton, M., Karbon, W., Scherrer, J., Shatzen, E., Rishton, G., Scully, S., Qi, M., Harris, R., Lacey, D., and Martin, D. (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl, J. Pharmacol. Exp. Ther. 308, 627-35.
38. Knoflach, F., Mutel, V., Jolidon, S., Kew, J. N., Malherbe, P., Vieira, E., Wichmann, J., and Kemp, J. A. (2001) Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action, and binding site, Proc. Natl. Acad. Sci. U.S.A. 98, 13402-7.
39. Maj, M., Bruno, V., Dragic, Z., Yamamoto, R., Battaglia, G., Inderbitzin, W., Stoehr, N., Stein, T., Gasparini, F., Vranesic, I., Kuhn, R., Nicoletti, F., and Flor, P. J. (2003) (-)-PHCCC, a positive allosteric modulator of mGluR4: Characterization, mechanism of action, and neuroprotection, Neuropharmacology 45, 895-906.
40. O'Brien, J. A., Lemaire, W., Wittmann, M., Jacobson, M. A., Ha, S. N., Wisnoski, D. D., Lindsley, C. W., Schaffhauser, H. J., Rowe, B., Sur, C., Duggan, M. E., Pettibone, D. J., Conn, P. J., and Williams, D. L. J. (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain, J. Pharmacol. Exp. Ther. 309, 568-77.
41. Rodriguez, A. L., Nong, Y., Sekaran, N. K., Alagille, D., Tamagnan, G. D., and Conn, P. J. (2005) A close structural analog of 2-methyl-6- (phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators, Mol. Pharmacol. 68, 1793-802.
42. Price, M. R., Baillie, G. L., Thomas, A., Stevenson, L. A., Easson, M., Goodwin, R., McLean, A., McIntosh, L., Goodwin, G., Walker, G., Westwood, P., Marrs, J., Thomson, F., Cowley, P., Christopoulos, A., Pertwee, R. G., and Ross, R. A. (2005) Allosteric modulation of the cannabinoid CB1 receptor, Mol. Pharmacol. 68, 1484-95.
43. Hoare, S. R., Sullivan, S. K., Ling, N., Crowe, P. D., and Grigoriadis, D. E. (2003) Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists, Mol. Pharmacol. 63, 151-65.
44. Watson, C., Jenkinson, S., Kazmierski, W., and Kenakin, T. (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor, Mol. Pharmacol. 67, 1268-82.
45. Litschig, S., Gasparini, F., Rueegg, D., Stoehr, N., Flor, P. J., Vranesic, I., Prezeau, L., Pin, J. P., Thomsen, C. P., and Kuhn, R. (1999) CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding, Mol. Pharmacol. 55, 453-61.
46. Pagano, A., Ruegg, D., Litschig, S., Stoehr, N., Stierlin, C., Heinrich, M., Floersheim, P., Prezeau, L., Carroll, F., Pin, J. P., Cambria, A., Vranesic, I., Flor, P. J., Gasparini, F., and Kuhn, R. (2000) The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b] criromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors, J. Biol. Chem. 275, 33750-8.
47. Zahn, K., Eckstein, N., Trankle, C., Sadee, W., and Mohr, K. (2005) Allosteric modulation of muscarinic receptor signaling: Alcuronium-induced conversion of pilocarpine from an agonist into an antagonist, J. Pharmacol. Exp. Ther. 301, 720-8.
48. Parmentier, M. L., Prezeau, L., Bockert, J., and Pin, J. P. (2002) A model for the functioning of family 3 GPCRs, Trends Pharmacol. Sci. 23, 268-74.
49. Anderes, K. L., Luthin, D. R., Castillo, R., Kraynov, E. A., Castro, M., Nared-Hood, K., Gregory, M. L., Pathak, V. P., Christie, L. C., Paderes, G., Vazir, H., Ye, Q., Anderson, M. B., and May, J. M. (2003) Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats, J. Pharmacol. Exp. Ther. 305, 688-95.
50. Luthin, D. R., Hong, Y., Tompkins, E., Anderes, K. L., Paderes, G., Kraynov, E. A., Castro, M. A., Nared-Hood, K. D., Castillo, R., Gregory, M., Vazir, H., May, J. M., and Anderson, M. B. (2002) Characterization of mono- and diaminopyrimidine derivatives as novel, nonpeptide gonadotropin releasing hormone (GnRH) receptor antagonists, Bioorg. Med. Chem. Lett. 12, 3635-9.
51. Luthin, D. R., Hong, Y., Pathak, V. P., Paderes, G., Nared-Hood, K. D., Castro, M. A., Vazir, H., Li, H., Tompkins, E., Christie, L., May, J. M., and Anderson, M. B. (2002) The discovery of novel small molecule non-peptide gonadotropin releasing hormone (GnRH) receptor antagonists, Bioorg. Med. Chem. Lett. 12, 3467-70.
52. Tucci, F. C., Zhu, Y. F., Struthers, R. S., Guo, Z., Gross, T. D., Rowbottom, M. W., Acevedo, O., Gao, Y., Saunders, J., Xie, Q., Reinhart, G. J., Liu, X. J., Ling, N., Bonneville, A. K., Chen, T., Bozigian, H., and Chen, C. (2005) 3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3- methoxyphenyl)-6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization, J. Med. Chem. 48, 1169-78.
53. Struthers, R. S., Xie, Q., Sullivan, S. K., Reinhart, G. J., Kohout, T. A., Zhu, Y. F., Chen, C., Liu, X. J., Ling, N., Yang, W., Maki, R., Bonneville, A. K., Chen, T., and Bozigian, H. Pharmacological Characterization of a Novel Nonpeptide Antagonist of the Human GnRH Receptor, NBI-42902, Endocrinology, in press.
54. Sullivan, S. K., Hoare, S. R. J., Fleck, B. F., Zhu, Y. F., Heise, C. E., Struthers, R. S., and Crowe, P. D. (2006) Kinetics of Nonpeptide Antagonist Binding to the Human Gonadotropin Releasing Hormone Receptor: Implications for Structure-Activity Relationships and Insurmountable Antagonism, Biochem. Pharmacol. (in press).
55. Struthers, R. S., Chen, T., Campbell, B., Jimenez, R., Pan, H., Yen, S. C., and Bozigian, H. (2006) Suppression of Serum Luteinizing Hormone in Postmenopausal Women by an Orally Administered Nonpeptide Antagonist of the Gonadotropin-Releasing Hormone Receptor (NBI-42902), J. Clin. Endocrinol. Metab. (in press).
56. Ballasteros, J., and Weinstein, H. (1995) Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors, Methods Neurosci. 25, 366-428.
57. Anderson, M. B., Vazir, H. N., Luthin, D. R., Paderes, G. D., Pathak, V. P., Christie, L. C., Hong, Y., Tomkins, E. V., Li, H., and Faust, J. (2000) Non-peptide GnRH agents, methods and intermediates for their preparation, Chem. Abstr. 132, 279106.
58. Flanagan, C. A., Fromme, B. J., Davidson, J. S., and Millar, R. P. (1998) A high affinity gonadotropin-releasing hormone (GnRH) tracer, radioiodinated at position 6, facilitates analysis of mutant GnRH receptors, Endocrinology 139, 4115-9.
59. Reinhart, G. J., Xie, Q., Liu, X. J., Zhu, Y. F., Fan, J., Chen, C., and Struthers, R. S. (2004) Species selectivity of nonpeptide antagonists of the gonadotropin-releasing hormone receptor is determined by residues in extracellular loops II and III and the amino terminus, J. Biol. Chem. 279, 34115-22.
60. Myburgh, D. B., Pawson, A. J., Davidson, J. S., Flanagan, C. A., Millar, R. P., and Hapgood, J. P. (1998) A single amino acid substitution in transmembrane helix VI results in overexpression of the human GnRH receptor, Eur. J. Endocrinol. 139, 438-47.
61. Benjamin, E. R., Haftl, S. L., Xanthos, D. N., Crumley, G., Hachicha, M., and Valenzano, K. J. (2004) A miniaturized column chromatography method for measuring receptor-mediated inositol phosphate accumulation, J. Biomol. Screening 9, 343-53.
62. Halgren, T. A. (1999) MMFF VI. MMFF94s Option for Energy Minimization Studies, J. Comput. Chem. 20, 720-9.
63. Halgren, T. A. (1999) MMFF VII. Characterization of MMFF94, MMFF94s, and Other Widely Available Force Fields for Conformational Energies and for Intermolecular-Interaction Energies and Geometries, J. Comput. Chem. 20, 730-48.
64. Lu, Z. L., Gallagher, R., Sellar, R., Coetsee, M., and Millar, R. R. (2005) Mutations remote from the human gonadotropin-releasing hormone (GnRH) receptor binding sites specifically increase binding affinity for GnRH II, but not GnRH I: Evidence for ligand-selective receptor active conformations, J. Biol. Chem. 280, 29796-803.
65. Soderhall, J. A., Polymeropoulos, E. E., Paulini, K., Gunther, E., and Kuhne, R. (2005) Antagonist and agonist binding models of the human gonadotropin-releasing hormone receptor, Biochem. Biophys. Res. Commun. 333, 568-82.
66. Flanagan, C. A., Becker, I. I., Davidson, J. S., Wakefield, I. K., Zhou, W., Sealfon, S. C., and Millar, R. P. (1994) Glutamate 301 of the mouse gonadotropin-releasing hormone receptor confers specificity for arginine 8 of mammalian gonadotropin-releasing hormone, J. Biol. Chem. 269, 22636-41.
67. Fromme, B. J., Katz, A. A., Roeske, R. W., Millar, R. P., and Flanagan, C. A. (2001) Role of aspartate 7.32 (302) of the human gonadotropin-releasing hormone receptor in stabilizing a high affinity ligand conformation, Mol. Pharmacol. 60, 1280-7.
68. Kenakin, T. (2004) A Pharmacology Primer: Theory, Application, and Methods, pp 105-7, Elsevier Academic Press, San Diego.
69. Hall, D. A. (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: An extension of the two-state model of receptor activation, Mol. Pharmacol. 58, 1412-23.
70. Hardy, J. A., and Wells, J. A. (2004) Searching for new allosteric sites in enzymes, Curr. Opin. Struct. Biol. 14, 706-15.
71. Christopoulos, A., Pierce, T. L., Sorman, J. L., and El-Fakahany, E. E. (1998) On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor, Mol. Pharmacol. 53, 1120-30.
72. Soudijn, W., van Wijngaarden, I., and Uzerman, A. P. (2002) Allosteric modulation of G protein-coupled receptors, Curr. Opin. Drug Discovery Dev. 5, 749-55.